200 completed, 36 unknown, 26 recruiting, 13 active not recruiting. 98 Phase 1, 93 Phase 2, 67 Phase 3, 41 Phase 4, 14 Not applicable.
Follow Vaccines: new trials by email Literature Review of Vaccines trials Research Report on Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib) Hexavalent (DTwP-HepB-rPV-Hib) Vaccine, HEXASIIL - Diptheria Immunization, Tetanus Immunization | Phase 1 / Phase 2 | Recruiting | Serum Institute of India Pvt. Ltd. | 186 | 2026-11-01 | 2026-11-10 |
| Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Acne mRNA (messenger ribonucleic acid) vaccine, Placebo - Acne | Phase 2 | Not yet recruiting | Sanofi | 410 | 2026-10-30 | 2026-09-18 |
| Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above. Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant - Healthy Volunteers, Influenza | Phase 1 / Phase 2 | Recruiting | Sanofi | 640 | 2026-08-03 | 2026-09-15 |
| Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal Cancer Biological/Vaccine - Advanced Gastrointestinal Cancer | Phase 1 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 20 | 2026-08-01 | 2026-07-29 |
| A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults Pan-Salmonella-with-Alum (Low dose) vaccine, Pan-Salmonella-with-Alum (Full dose) vaccine, Pan-Salmonella-without-Alum (Low dose) vaccine - Salmonella Infections | Phase 1 | Recruiting | GlaxoSmithKline | 196 | 2026-06-24 | 2026-07-28 |
| A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine - Respiratory Syncytial Virus Infections+Metapneumovirus | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 1456 | 2026-06-05 | 2026-10-01 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| IMP3-saRNA Vaccine in Advanced NSCLC IMP3-saRNA (YMN-136) Vaccine - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | West China Hospital | 9 | 2026-04-30 | 2026-05-12 |
| Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST) Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline - Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous | Phase 2 | Recruiting | University of Virginia | 48 | 2026-04-27 | 2026-05-27 |
| Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization Autologous total tumor mRNA loaded DOTAP liposome vaccine - Melanoma, Soft Tissue Sarcoma | Phase 1 | Suspended | University of Florida | 18 | 2026-03-17 | 2026-09-17 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine - Influenza, Human+COVID-19 | Phase 1 | Recruiting | GlaxoSmithKline | 225 | 2026-03-09 | 2026-06-30 |
| Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) Dengue 1,2,3,4 (attenuated) vaccine - Dengue | Phase 3 | Active not recruiting | Butantan Institute | 997 | 2026-03-03 | 2026-11-10 |
| A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years Tuberculosis (TB) vaccine (Ad5-105K), Placebo, Ad5-105K - Tuberculosis | Phase 1 | Active not recruiting | CanSino Biologics Inc. | 36 | 2025-11-13 | 2026-04-30 |
| Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV, Vaxigrip QIV - Influenza | Phase 3 | Completed | Sinovac Biotech Co., Ltd | 150 | 2025-10-13 | 2026-11-10 |
| Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients Commercial measles, mumps, and rubella (MMR) vaccine - Heart Transplant Infection Prevention | Phase 4 | Recruiting | Children's Mercy Hospital Kansas City | 60 | 2025-09-11 | 2026-09-24 |
| A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo. Vaccine, Placebo - RSV Infections, RSV Immunisation | Phase 3 | Recruiting | University of Witwatersrand, South Africa | 13000 | 2025-09-03 | 2026-05-18 |
| Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure Vaccine injection - Vaccination; Infection | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 735 | 2025-09-03 | 2026-05-15 |
| Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) In-House Recombinant Hepatitis B (Bio Farma) vaccine, Registered Hepatitis B vaccine recombinant (Engerix-B) - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Not yet recruiting | PT Bio Farma | 540 | 2025-09-01 | 2025-06-06 |
Showing 20 of 307. Sign in to see all of them.
Influenza, Human (33) · COVID-19 (23) · Meningococcal Infections (13) · Dengue (12) · Haemophilus Infections (12) · Papillomavirus Infections (12) · Uterine Cervical Neoplasms (12) · HIV Infections (10) · Herpes Zoster (10) · Neoplasms (10) · Breast Neoplasms (9) · Encephalitis, Tick-Borne (9) · Infections (8) · Uterine Cervical Dysplasia (8) · Meningitis (7)
GlaxoSmithKline (33) · Sanofi Pasteur, a Sanofi Company (22) · National Institute of Allergy and Infectious Diseases (NIAID) (16) · Pfizer (13) · Merck Sharp & Dohme LLC (9) · U.S. Army Medical Research and Development Command (9) · Butantan Institute (7) · H. Lee Moffitt Cancer Center and Research Institute (7) · Novartis Vaccines (7) · Beijing Health Guard Biotechnology, Inc (5) · PT Bio Farma (5) · University of Oxford (5) · Assistance Publique - Hôpitaux de Paris (4) · National Cancer Institute (NCI) (4) · Novartis (4)
United States (105) · China (31) · Brazil (17) · Spain (13) · United Kingdom (13) · France (12) · Australia (10) · Germany (10) · Poland (10) · Bangladesh (9) · Finland (9) · Austria (8) · Canada (8) · Italy (8) · Russia (8)
Ting Wu, Ph. D. (4) · Yongjiang Liu, Bachelor (4) · Hoyoung M Maeng, M.D. (3) · Phillip R Pittman, MD, MPH (3) · Anna Durbin, MD (2) · David JM Lewis, MD (2) · Fernanda C Boulos, MD, PhD (2) · Jerzy Brzostek, MD (2)
PMID 39116904, PMID 21975270, PMID 23964690, PMID 24290843, PMID 30876830, PMID 31362741, PMID 31798645, PMID 32220283, PMID 32665955, PMID 37781954, PMID 38294972, PMID 40237463, PMID 40396505, PMID 10526739, PMID 106465, PMID 11202234, PMID 12493340, PMID 15079177, PMID 15302746, PMID 16012514, PMID 16417952, PMID 17425783, PMID 18025879, PMID 18337339, PMID 18463125, PMID 19416838, PMID 19649245, PMID 19875605, PMID 20018367, PMID 20210645, PMID 20439595, PMID 20864808, PMID 20930072, PMID 21150468, PMID 21177912, PMID 21248158, PMID 21384334, PMID 21419775, PMID 21422117, PMID 21445325, PMID 21592984, PMID 21903775, PMID 21984924, PMID 22011412, PMID 22153001, PMID 22228003, PMID 22312016, PMID 22469863, PMID 22542645, PMID 22566415
2023 (3), 2014 (2), 2016 (2), 2017 (2), 2025 (2), 2005 (1), 2008 (1), 2009 (1), 2018 (1), N01AI30039 (1), P30CA076292 (1), P50CA098252 (1), R01AG068568 (1), R01CA112198 (1), R01NS112712 (1)